Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116136 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
A Phase 1 study of MSI-H/dMMR Gastric Cancer and MSI-H/dMMR Gastroesophageal-junction Cancer, sponsored by Servier Bio-Innovation.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT06116136 is a Phase 1 study of MSI-H/dMMR Gastric Cancer and MSI-H/dMMR Gastroesophageal-junction Cancer that is active but no longer recruiting, run by Servier Bio-Innovation. The registered enrollment target is 48 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT06116136, a Phase 1 study of MSI-H/dMMR Gastric Cancer and MSI-H/dMMR Gastroesophageal-junction Cancer, is active but no longer recruiting, sponsored by Servier Bio-Innovation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.
Conditions Studied
Interventions
- DRUG S095029
- DRUG pembrolizumab 200 mg (KEYTRUDA ®)
Study Locations (20)
Other
- The Queen Elizabeth Hospital - Woodville South
- Landeskrankenhaus (SALK) - Salzburg
- UZ Leuven Campus Gasthuisberg - Leuven
- Chu de Liege - Liège
- Cepon - Centro de Pesquisas Oncologicas - Florianópolis
- Supera Oncologia - Santa Catarina
- Icesp - Instituto Do Câncer Do Estado de São Paulo - São Paulo
- Instituto Brasileiro de Controle Do Câncer - São Paulo
- Hospital Albert Einstein - São Paulo
- Mount Sinai Hospital - Toronto
Florida
- Ocala Oncology Center Pl - Ocala
Indiana
- Investigative Clinical Research of Indiana, Llc - Noblesville
Texas
- MD Anderson Cancer Center - Houston
Upper Austria
- Ordensklinikum Linz - Linz
Vienna
- Med Universitat Wien-Allgemeines Krankenhaus Der Stadt Wien (AKH) - Vienna
Beijing Municipality
- Beijing Cancer Hospital - Beijing
Heilongjiang
- Harbin Medical University Cancer Hospital - Harbin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-08-31 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06116136
The ClinicalTrials.gov registry entry for NCT06116136 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Servier Bio-Innovation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with MSI-H/dMMR Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which S095029 is the first listed.
NCT06116136 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT06116136 about?
NCT06116136 is a clinical study titled "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.". This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.
What is the current status of trial NCT06116136?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-08-31. Estimated completion is 2026-08.
What conditions does trial NCT06116136 study?
This clinical trial studies the following conditions: MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT06116136?
The interventions under investigation include: S095029 (DRUG), pembrolizumab 200 mg (KEYTRUDA ®) (DRUG).
Who is sponsoring clinical trial NCT06116136?
This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116136 being conducted?
This trial has 20 study locations across Florida, Indiana, Texas, Upper Austria, Vienna. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MSI-H/dMMR Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
MSI-H/dMMR Gastric Cancer
All registered trials for this condition
MSI-H/dMMR Gastroesophageal-junction Cancer
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.